Although restricted to 365 days of follow-up , this analysis encapsulates 1366 of 1424 ( 95.9 % ) of all primary endpoint events and 244 of 257 ( 94.9 % ) of all first non-CABG TIMI major bleeds reported in the pivotal manuscript .